NCT07007936

Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial to Evaluate the Efficacy and Safety of Oral SSS17 Capsules in the Treatment of Anemia Following Total Hip or Knee Arthroplasty

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To assess the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of orally administered SSS17 capsules in patients with postoperative anemia following elective total hip or knee arthroplasty.

Conditions

• Postoperative Anemia
• Arthroplasty, Replacement, Hip
• Arthroplasty, Replacement, Knee

Interventions

Type	Name	Description
DRUG	SSS17 Capsule (6 Dose Levels)	Arm1 ： This dose-ranging study evaluates 6 dose levels of oral SSS17 capsules under two regimens: Once weekly、 Twice weekly
DRUG	Placebo Drug	Arm2：placebo The placebo intervention was matched with the six dose levels of SSS17, with each dose level assigning participants in a ratio of 4:1 (SSS17 to placebo).

Timeline

• Start date: 2025-07-01
• Primary completion: 2026-04-01
• Completion: 2026-04-01
• First posted: 2025-06-06
• Last updated: 2025-06-11

Locations

1 site across 1 country: China